View:

Download DOC

Download PDF

Download XLS

Table of Contents

Table of Contents

                                                                    EXHIBIT 99.1


Contact:
McDavid Stilwell
GTx, Inc.
Manager, Corporate Communications & Financial Analysis
901-523-9700

    GTX, INC. ANNOUNCES INITIATION OF PHASE IIIB EXTENSION TRIAL OF ACAPODENE
       FOR THE TREATMENT OF SIDE EFFECTS OF ANDROGEN DEPRIVATION THERAPY


MEMPHIS, TENN. -- April 21, 2006--GTx, Inc. (Nasdaq: GTXI), the Men's Health
Biotech Company, today announced it is initiating a separate Phase IIIb clinical
trial as an extension of the pivotal Phase III ADT clinical trial of
ACAPODENE(R) (toremifene citrate) in an 80mg dose for the treatment of multiple
serious side effects of androgen deprivation therapy.

Prostate cancer patients in the pivotal Phase III ADT trial who have completed
the full two year treatment will be eligible to participate in the Phase IIIb
extension trial for an additional year. The purpose of this study is to collect
additional efficacy and safety data that could further support the current Phase
III clinical study. This additional Phase IIIb clinical study is considered to
be a separate clinical trial and will not affect the current timeline for the
completion of the ongoing Phase III clinical trial in the second half of 2007
and the potential submission of the new drug application.

"This new clinical trial is a unique opportunity to continue to follow in a
blinded fashion ADT patients completing our two year pivotal Phase III study. It
will allow us not only to obtain additional data regarding fractures and safety,
but also to evaluate other possible benefits of ACAPODENE in this population,"
said Mitchell S. Steiner, M.D., CEO of GTx.

Approximately 1,400 men have been enrolled into the pivotal Phase III clinical
trial evaluating ACAPODENE for the treatment of side effects of androgen
deprivation therapy for advanced prostate cancer. GTx completed enrollment of
the trial in the fall of 2005. The primary endpoint of the trial, which is being
conducted under a Special Protocol Assessment with the United States Food & Drug
Administration, is a reduction in vertebral fractures. Secondary endpoints
include improvements in bone mineral density and cholesterol levels, a reduction
in hot flashes, and the treatment of gynecomastia. In December 2005, GTx
conducted an interim analysis of bone mineral density in the first 200 men to
complete one full year of treatment. The interim





analysis demonstrated a highly statistically significant positive change in bone
mineral density in patients treated with ACAPODENE versus patients on placebo.


ABOUT GTX

GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated
to the discovery, development and commercialization of therapeutics for cancer
and serious conditions related to men's health. GTx's lead drug discovery and
development programs are focused on small molecules that selectively modulate
the effects of estrogens and androgens, two essential classes of hormones. GTx
is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor
modulator, or SERM, in two separate clinical programs in men: first, a pivotal
Phase III clinical trial for the treatment of serious side effects of androgen
deprivation therapy for advanced prostate cancer, and second, a pivotal Phase
III clinical trial for the prevention of prostate cancer in high risk men with
high grade PIN. GTx also is developing ostarine, a selective androgen receptor
modulator, or SARM, for a variety of indications including muscle wasting and
bone loss in frail elderly patients, osteoporosis, muscle wasting in end stage
renal disease patients, and severe burn wounds and associated muscle wasting.
GTx has licensed to Ortho Biotech Products, L.P., a subsidiary of Johnson &
Johnson, another of its SARMs, andarine, under a joint collaboration and license
agreement.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's current
expectations. Forward-looking statements involve risks and uncertainties. GTx's
actual results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the risks that (i) GTx will
not be able to commercialize its product candidates if clinical trials do not
demonstrate safety and efficacy in humans; (ii) GTx may not able to obtain
required regulatory approvals to commercialize its product candidates; (iii)
GTx's clinical trials may not be completed on schedule, or at all, or may
otherwise be suspended or terminated; and (iv) GTx could utilize its available
cash resources sooner than it currently expects and may be unable to raise
capital when needed, which would force GTx to delay, reduce or eliminate its
product development programs or commercialization efforts. You should not place
undue reliance on these forward-looking statements, which apply only as of the
date of this press release. GTx's annual report on form 10-K filed with the U.S.
Securities and Exchange Commission on March 2, 2006, contains a more
comprehensive description of these and other risks to which GTx is subject. GTx
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements are based.